AbbVie said today it has received U.S. Food & Drug Administration approval of Skyrizi for adults with moderately to severely active ulcerative colitis, further bolstering its pipeline of drugs that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback